Cipla gains on entering into agreement with MannKind Corporation for Afrezza

10 May 2018 Evaluate

Cipla is currently trading at Rs. 591.50, up by 2.30 points or 0.39% from its previous closing of Rs. 589.20 on the BSE.

The scrip opened at Rs. 593.15 and has touched a high and low of Rs. 595.35 and Rs. 591.50 respectively. So far 4,869 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 663.00 on 07-Nov-2017 and a 52 week low of Rs. 479.00 on 26-May-2017.

Last one week high and low of the scrip stood at Rs. 617.60 and Rs. 584.85 respectively. The current market cap of the company is Rs. 47,578.00 crore.

The promoters holding in the company stood at 37.21%, while Institutions and Non-Institutions held 38.10% and 24.69% respectively.

Cipla has entered into an exclusive marketing and distribution agreement with US-based MannKind Corporation for Afrezza in India. Afrezza is the only USFDA approved inhaled insulin available for patients suffering from diabetes.

Under the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI). Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1466.05 -0.10 (-0.01%)
12-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1736.85
Dr. Reddys Lab 1215.65
Cipla 1466.05
Zydus Lifesciences 895.00
Lupin 2189.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×